This clinical study is evaluating a potential new drug for to treat IBD. IBD is a term used to describe conditions that cause abdominal pain and diarrhoea, among other symptoms.
The study drug is designed to reduce the inflammatory response that causes IBD symptoms.
The study is a randomised, double-blind, placebo-controlled trial. The purpose of this study is to assess the safety and tolerability of a single dose in healthy men and women with a BMI of 18–35.
Be 18 to 55 years old
Both males or females
